Clinical trial
Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2…
NCT00174993 · Takeda, Industry · Completed
Key facts
| NCT number | NCT00174993 |
|---|---|
| Title | Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes |
| Official title | PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy |
| Acronym | PROactive |
| Lead sponsor | Takeda, Industry |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Pioglitazone, Placebo |
| Enrollment | 4,373 |
| Start date | May 1, 2001 |
| Primary completion | Jan 1, 2005 |
| Completion | Jan 1, 2005 |
| First posted | Sep 15, 2005 |
| Last update posted | Feb 28, 2012 |
| Countries | Austria, Belgium, Czechia, Denmark, Estonia, Finland, France, Germany, Hungary, Italy, Latvia, Lithuania and 7 more |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: